Drug Profile
Research programme: anti-proliferative therapeutics - DiscoveryBioMed
Latest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator DiscoveryBioMed
- Developer DiscoveryBioMed; University of Maryland School of Medicine
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autosomal dominant polycystic kidney disease